A Limited number of previous case reports have described the successful of crizotinib, ceritinib, alectinib or brigatinib in patients with ALK-rearranged NSCLC who have recovered from pneumonitis secondary to ALK-TKIs [6,7,9,10]. Here, ALK is linked to non-small cell lung carcinoma.